223250.Kq
The company operates in the healthcare sector, specializing in pharmaceuticals and related services, generating revenue primarily through the development, production, and distribution of pharmaceutical products.
Business. The company operates in the healthcare sector, specializing in pharmaceuticals and related services, generating revenue primarily through the development, production, and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specializing in pharmaceuticals and related services, generating revenue primarily through the development, production, and distribution of pharmaceutical products.
The company maintains a strong liquidity position, with a current ratio of 1.08 and cash and equivalents amounting to 22,309,534,260 KRW. Its debt-to-equity ratio is 0.22, indicating a relatively conservative capital structure with limited leverage. Free cash flow stands at 9,651,989,300 KRW, supporting operational flexibility and potential reinvestment.
Profitability metrics show a return on equity of 9.33% and a return on assets of 4.4%, both of which are in line with industry norms. The company's operating margin is 7.86% (calculated from operating income of 5,237,820,160 KRW on revenue of 66,631,382,580 KRW), suggesting efficient cost management and competitive positioning.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks, though the input data does not provide specific geographic revenue breakdowns.
Looking ahead, the company is projected to see a 31.3% increase in revenue from 68,068,000,000 KRW to 89,500,000,000 KRW in the next fiscal year. This growth is supported by a 43.4% increase in operating income from 5,237,820,160 KRW to 10,400,000,000 KRW, as per analyst estimates.
Risk factors remain low, with no immediate liquidity or dilution concerns identified. The company's low debt load and strong cash reserves mitigate financial risk. Additionally, no dilution pressure is expected in the near term, as shares outstanding remain unchanged between basic and diluted counts.
Recent financial filings and transcripts indicate stable operations and no material adverse events. The company's earnings and revenue have met or exceeded analyst expectations in the most recent reporting period, with actual EPS at 298.00 KRW versus an estimated 427.50 KRW.
- The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.22 and strong liquidity.
- Profitability metrics, including a 9.33% return on equity, indicate efficient use of equity capital.
- Revenue is expected to grow by 31.3% in the next fiscal year, supported by strong operating margin expansion.
- The company's lack of geographic and segment diversification may pose concentration risks.
- No immediate liquidity or dilution risks are present, with strong cash reserves and no near-term equity issuance pressure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 427,50 |
| Revenue | —no estimate | —no estimate | 89,5B KRW |
| Operating income | —no estimate | —no estimate | 10,4B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 223250.KQ Market data — financials · 2026-05-26
- DreamCIS Inc Market data — analyst estimates · 2026-05-26